ClinicalTrials.gg
Active, not recruitingNCT06151600CMT4JUpdated Jul 8, 2026

A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J

An observational study in Peripheral Neuropathy, Neuro-Degenerative Disease and Neuromuscular Diseases, sponsored by Elpida Therapeutics SPC. Active, not recruiting at 3 sites in United States. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Elpida Therapeutics SPC · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
20
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 191 studies in Peripheral Nervous System Diseases with a site in United States — 31 open to participants now, 48 under way, 2 of them phase 3. Peripheral Nervous System Diseases · United States.

Planned enrollment
25th of 31
20 · median 80
Started
2024
with 4 others
Observational
31 of 191
6 open now
Primary completion
2031-03
later than 46 of 46 live
Registered
168th of 191
by date

Among the 191 studies in Peripheral Nervous System Diseases with a site in United States, this one is the 25th largest by planned enrollment of the 31 observational ones that give a count, is one of 5 that started in 2024, is one of 31 observational ones, reaches primary completion later than 46 of the 46 other live ones, and was the 168th registered.

Peripheral Nervous System Diseases

476 studies on the registry are indexed under Peripheral Nervous System Diseases; 103 are open to participants now.

Browse Peripheral Nervous System Diseases studies →

Open to participants now

31 of the 191 studies in Peripheral Nervous System Diseases with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 65 Peripheral Nervous System Diseases studies recruiting now, 44 (68%) set no upper age limit and 10 (15%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 191 studies in Peripheral Nervous System Diseases with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, longitudinal, prospective observational natural history study of subjects with a molecularly confirmed diagnosis of CMT4J. The study will enroll 20 subjects of any age into a uniform protocol for follow-up and evaluations. Subject visits will occur every 12 months + 4 weeks for up to 2 years.

Read the detailed description

This is a multicenter, longitudinal, prospective observational natural history study of subjects with a molecularly confirmed diagnosis of CMT4J. The study will enroll 20 subjects of any age into a uniform protocol for follow-up and evaluations. The study will obtain demographic and medical history information. Natural history data will be collected prospectively on an annual basis and may include physical/neurological exams, standard laboratory tests, CMT outcome and disability measures, neuropsychological tests, nerve conduction studies (NCS), and imaging studies (muscle MRI). Pulmonary function test (PFT) and scoliosis series x-ray Subject visits will occur every 12 months + 4 weeks for up to 2 years. Subjects who terminate from the study prior to Visit 3 will undergo an early termination/end of study visit (EOS) if possible. The early termination/end of study visit is comprised of the Visit 3 assessments. If needed, the Investigator may conduct unscheduled visits with Sponsor's approval. No investigational product will be used during the study.

03

Conditions studied

  • Peripheral Neuropathy
  • Neuro-Degenerative Disease
  • Neuromuscular Diseases
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects with a genetically confirmed diagnosis of CMT4J will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, all ages
  2. A molecularly-confirmed diagnosis of CMT4J (confirmed by a CLIA certified, CE-marked, or equivalent lab): Genomic DNA mutation analysis demonstrating 1) bi-allelic pathogenic and/or likely pathogenic variants (by ACMG criteria) in the FIG4 gene, or 2) bi-allelic variants with one pathogenic and/or likely pathogenic variant in trans with a variant of uncertain significance if laboratory evidence and expert consensus exits in support of loss of FIG4 function exists.
  3. from patients 18 years or older who are able to provide consent and from caregivers; parent(s)/guardian(s) providing consent for subjects younger than 18 years at Screening and patients older than 18 years unable to provide informed consent
  4. Informed assent of patients younger than 18 years at Screening who are able to provide assent
  5. Able and willing to comply with the study protocol, including travel to Study Center, procedures, measurements and visits

Exclusion criteria

Exclusion Criteria:

  1. Any known genetic abnormality, including chromosomal aberrations that confound the clinical phenotype
  2. Current participation in an interventional or therapeutic study
  3. Receiving an drug within 90 days of the Baseline Visit
  4. Prior or current treatment with gene or stem cell therapy
  5. Any other diseases which may significantly interfere with the assessment of CMT4J
  6. Have any other conditions, which, in the opinion of the Investigator or Sponsor would make the subject unsuitable for inclusion or could interfere with the subject participating in or completing the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Study objective

    This study is designed to investigate the clinical characteristics and natural history of CMT4J.

    Time frame: 2 years

07

Study locations

3 sites
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified data for publication.

Supporting information: Study protocol, Informed consent form, Clinical study report

Time frame: Starting in January 2025

Access criteria: All Investigators leading the trial.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Mar 2031, 79 months after the start.

Of 38 observational studies under Peripheral Nervous System Diseases, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 93. This study's planned 79 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Nov 30, 2023
StartActual
Jul 29, 2024
Primary completionEst.
Mar 1, 2031
CompletionEst.
Mar 1, 2032
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06151600
Lead sponsor
Elpida Therapeutics SPC
Responsible party
Sponsor
First posted
Nov 30, 2023
Start date
Jul 29, 2024
Primary completion
Mar 1, 2031 (estimated)
Completion
Mar 1, 2032 (estimated)
Last update
Jul 8, 2026

Study contacts

Souad Messahel, Ph.D
study director · Elpida Therapeutics SPC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion